Magnetic resonance imaging detects differences in migration between primary and immortalized neural stem cells.
OBJECTIVE
The study was performed to evaluate the effect of magnetic resonance imaging (MRI) contrast agent (super paramagnetic iron oxide [SPIO]) on differentiation and migration of primary murine neural stem cells (NSCs) in comparison to a neural stem cell line (C17.2). Because detection of labeled cells depends on the concentration of SPIO particles per imaging voxel, the study was performed at various concentrations of SPIO particles to determine the concentration that could be used for in vivo detection of small clusters of grafted cells.


METHODS
Murine primary NSCs or C17.2 cells were labeled with different concentrations of SPIO particles (0, 25, 100, and 250 microg Fe/mL) and in vitro assays were performed to assess cell differentiation. In vivo MRI was performed 7 weeks after neonatal transplantation of labeled cells to evaluate the difference in migration capability of the two cell populations.


RESULTS
Both the primary NSCs and the C17.2 cells differentiated to similar number of neurons (Map2ab-positive cells). Similar patterns of engraftment of C17.2 cells were seen in transplanted mice regardless of the SPIO concentration used. In vivo MRI detection of grafted primary and C17.2 cells was only possible when cells were incubated with 100 microg/mL or higher concentration of SPIO. Extensive migration of C17.2 cells throughout the brain was observed, whereas the migration of the primary NSCs was more restricted.


CONCLUSIONS
Engraftment of primary NSCs can be detected noninvasively by in vivo MRI, and the presence of SPIO particles do not affect the viability, differentiation, or engraftment pattern of the donor cells.
Magnitsky
Sergey
S
Department of Radiology, School of Medicine, University of Pennsylvania, B6 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA.
Walton
Raquel M
RM
Wolfe
John H
JH
Poptani
Harish
H
D000818:Animals; D002460:Cell Line; D002465:Cell Movement / Q000502:physiology*; D003287:Contrast Media; D052203:Ferrosoferric Oxide; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D009474:Neurons / Q000166:cytology* / Q000502:physiology*; D013234:Stem Cells / Q000166:cytology* / Q000502:physiology*
D003287:Contrast Media; C427127:superparamagnetic blood pool agent; D052203:Ferrosoferric Oxide
Proc Natl Acad Sci U S A. 1990 May;87(10):3914-8
2111021
Nat Biotechnol. 2005 Nov;23(11):1407-13
16258544
Exp Neurol. 2005 Aug;194(2):301-19
16022860
Nat Rev Neurosci. 2006 May;7(5):395-406
16760919
J Neurobiol. 1990 Mar;21(2):356-75
2307979
Radiology. 2003 Aug;228(2):480-7
12819345
Nat Biotechnol. 2002 Nov;20(11):1103-10
12379867
Mol Ther. 2005 Jul;12(1):33-41
15963918
Bone Marrow Transplant. 2006 Jan;37(2):219-21
16299544
Magn Reson Med. 2007 Aug;58(2):261-9
17654572
Radiology. 2003 Dec;229(3):838-46
14657318
Magn Reson Med. 2003 May;49(5):968-71
12704781
Diabetes. 2006 Sep;55(9):2419-28
16936189
Neurosurgery. 2002 Oct;51(4):1043-52; discussion 1052-4
12234415
Cell. 1992 Jan 10;68(1):33-51
1732063
Nat Biotechnol. 1998 Nov;16(11):1033-9
9831031
Hum Gene Ther. 2004 Apr;15(4):351-60
15053860
Blood. 2004 Nov 15;104(10):3410-2; author reply 3412-3
15525839
Neuroscientist. 2005 Oct;11(5):408-16
16151043
Blood. 2003 Oct 1;102(7):2364-72
12763935
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7029-34
10359833
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16267-72
12444255
Nature. 1995 Mar 23;374(6520):367-70
7885477
Nat Biotechnol. 2001 Dec;19(12):1141-7
11731783
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3030-5
11867752
NMR Biomed. 2005 Dec;18(8):553-9
16229060
Hum Gene Ther. 2006 Jul;17(7):693-704
16839269
J Biomed Opt. 2007 Sep-Oct;12(5):051504
17994868
Exp Hematol. 2005 Sep;33(9):980-6
16140145
Magn Reson Med. 2003 Oct;50(4):767-76
14523963
NMR Biomed. 2007 Apr;20(2):77-89
16952123
Gene Ther. 2004 Aug;11(15):1175-87
15141158
Stroke. 2007 Jan;38(1):131-7
17122417
Front Biosci. 2006 Jan 01;11:1101-7
16146800
Nature. 2006 Jul 27;442(7101):365-6
16871201
Ann Neurol. 2002 Dec;52(6):762-70
12447930
Neurodegener Dis. 2007;4(4):314-21
17627135
Cytotherapy. 2004;6(6):621-5
15773025
Nat Biotechnol. 2002 Nov;20(11):1111-7
12379868
Eur Radiol. 2005 Jan;15(1):4-13
15616814
Neuroimage. 2004 Jan;21(1):311-7
14741669
J Neurochem. 2006 Apr;97(1):69-78
16524380
Q J Nucl Med Mol Imaging. 2005 Dec;49(4):349-60
16407818
NMR Biomed. 2004 Nov;17(7):513-7
15526348
Methods Enzymol. 2004;386:275-99
15120257
Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1312-21
15138719
Ann Surg Oncol. 1999 Oct-Nov;6(7):691-8
10560856
Mol Imaging. 2005 Jul-Sep;4(3):143-64
16194447
Neuroimage. 2005 Jul 1;26(3):744-54
15955483
Crit Rev Oncol Hematol. 2004 Sep;51(3):191-204
15331078
J Neurosci. 1999 Jul 15;19(14):5990-6005
10407037
J Neurosci Res. 2004 Apr 15;76(2):232-43
15048921
Q J Nucl Med. 2000 Sep;44(3):224-35
11105587
NeuroRx. 2005 Apr;2(2):215-25
15897946
J Clin Oncol. 1998 Jan;16(1):165-72
9440739
Nat Med. 1996 Apr;2(4):424-9
8597952
Hum Gene Ther. 2001 Mar 20;12(5):575-95
11268289
NMR Biomed. 2006 Aug;19(5):581-92
16673357
Neuroimage. 2005 Feb 1;24(3):635-45
15652299